Trexquant Investment’s Akero Therapeutics AKRO Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q4 | – | Sell |
-123,352
| Closed | -$5.86M | – | 1559 |
|
|
2025
Q3 | $5.86M | Buy |
123,352
+116,969
| +1,833% | +$5.66M | 0.06% | 490 |
|
|
2025
Q2 | $341K | Buy |
+6,383
| New | +$290K | ﹤0.01% | 1359 |
|
|
2024
Q4 | – | Sell |
-25,066
| Closed | -$719K | – | 1529 |
|
|
2024
Q3 | $719K | Buy |
25,066
+415
| +2% | +$10.8K | 0.01% | 1156 |
|
|
2024
Q2 | $578K | Buy |
+24,651
| New | +$527K | 0.01% | 1197 |
|
|
2023
Q4 | – | Sell |
-42,620
| Closed | -$2.16M | – | 1385 |
|
|
2023
Q3 | $2.16M | Buy |
42,620
+32,547
| +323% | +$1.52M | 0.05% | 469 |
|
|
2023
Q2 | $470K | Buy |
+10,073
| New | +$462K | 0.01% | 1032 |
|
|
2023
Q1 | – | Sell |
-22,830
| Closed | -$1.25M | – | 1406 |
|
|
2022
Q4 | $1.25M | Sell |
22,830
-18,337
| -45% | -$786K | 0.04% | 565 |
|
|
2022
Q3 | $1.4M | Buy |
41,167
+23,658
| +135% | +$362K | 0.05% | 437 |
|
|
2022
Q2 | $165K | Buy |
17,509
+5,593
| +47% | +$58.3K | 0.01% | 1394 |
|
|
2022
Q1 | $169K | Buy |
+11,916
| New | +$209K | 0.01% | 1229 |
|
|
2021
Q2 | – | Sell |
-8,343
| Closed | -$242K | – | 1052 |
|
|
2021
Q1 | $242K | Sell |
8,343
-109
| -1% | -$3.3K | 0.02% | 872 |
|
|
2020
Q4 | $218K | Buy |
8,452
+1,884
| +29% | +$52.4K | 0.02% | 850 |
|
|
2020
Q3 | $202K | Buy |
+6,568
| New | +$230K | 0.01% | 1076 |
|
Other funds holding AKRO
Trexquant Investment's AKRO Position: Q4 2025 in Review
Trexquant Investment sold out of Akero Therapeutics (AKRO) in Q4 2025, closing a stake of 123,352 shares — an estimated $5.86M sold.
Trexquant Investment first reported a position in AKRO in Q3 2020 and held it in 13 quarters. The position peaked at $5.86M in Q3 2025. 2 funds tracked by Wall St. Rank hold AKRO as of Q4 2025.
- Trexquant Investment reported no remaining Akero Therapeutics position as of Q4 2025 after selling out during the quarter.
- Trexquant Investment sold 123,352 Akero Therapeutics shares in Q4 2025, an estimated $5.86M.
- Trexquant Investment first reported a position in Akero Therapeutics in Q3 2020 and held it in 13 quarters.
- Trexquant Investment's Akero Therapeutics position peaked at $5.86M in Q3 2025.
- 2 funds tracked by Wall St. Rank held Akero Therapeutics as of Q4 2025.
Based on Trexquant Investment's 13F filing for Q4 2025, filed 17 Feb 2026.